Worldwide increase in diabetes forecasts renal disease explosion

[Guest guest]

Colleagues, the following is FYI; I have no further knowledge of the topic.

------------------------

On the edge: Are we at risk of an ESRD pandemic?

Worldwide increase in diabetes forecasts renal disease explosion

http://www.eurekalert.org/pub_releases/2004-05/rc-ote051704.php

An analysis of demographic data collected on European and American

patients participating in studies for a new non-calcium phosphate binder

show striking differences between the causes of renal failure: 14% of

European renal failure patients had diabetes as their primary diagnosis,

whereas 34% of US patients had this diagnosis.2 If, as expected by many

experts, the incidence of diabetes in Europe (estimated by the WHO to

rise from 33 million in 2000 to over 48 million by 20303) grows to match

that of the US, demand for renal replacement therapy in end stage renal

disease (ESRD) could escalate sharply.

" Patient demographic data from studies are extremely useful in helping

us understand the pattern of disease and the underlying causes of renal

failure " , commented lead investigator of the US study, Dr F.

Finn, Professor of Medicine, University of North Carolina School of

Medicine. " The question we have to ask ourselves is whether Europe will

follow the US, where increasing obesity is driving up the likelihood

that diabetes numbers will increase, thereby increasing the incidence of

diabetes-related renal failure. "

The studies in which these renal failure patients were enrolled were set

up to assess the efficacy and safety of FOSRENOL® (lanthanum carbonate),

a new phosphate binding medication recently granted its first regulatory

approval (in Sweden). Hyperphosphataemia (excessive levels of phosphate

in the blood) develops in up to 80% of patients on dialysis4 and can

lead to bone pain, skeletal deformities and fractures if left untreated.

It is also associated, in conjunction with elevated calcium levels, with

the development of cardiovascular disease, which accounts for nearly 50%

of all deaths in dialysis patients.5,6

Baseline screening data from the new studies also illustrated the

shortcomings of currently available hyperphosphataemia treatments. At

entry to the studies, calcium-based phosphate binders were the most

commonly used medication, both in the US (93%) and Europe (65%).2

However, serum phosphorus levels in these patients at study entry were

markedly higher than the target levels (3.5 to 5.5 mg/dL) recommended by

the new K/DOQI (Kidney Disease Outcomes Quality Initiative) guidelines7,

with a mean level of 6.6 mg/dL in the European patients and 6.2 mg/dL in

the US patients.2

In previous studies, FOSRENOL has been shown to be an effective and well

tolerated phosphate binder, lowering serum phosphate to target levels

within eight weeks and maintaining this long-term, with some patients

treated for 36 months (three years) or more.8,9 FOSRENOL therefore

represents a promising option for hyperphosphataemia management.

" There is no doubt that, with diabetes on the increase, end stage renal

disease will increase as well. To help our patients stay well, for as

long as possible while on dialysis, there is a pressing need for new and

effective treatments like FOSRENOL to help us manage serious

complications such as hyperphosphataemia " , concluded Dr Alastair

Hutchison, Manchester Institute of Nephrology & Transplantation, UK, who

led the European study.

--

ne Holden, MS, RD < fivestar@... >

" Ask the Parkinson Dietitian " http://www.parkinson.org/

" Eat well, stay well with Parkinson's disease "

" Parkinson's disease: Guidelines for Medical Nutrition Therapy "

http://www.nutritionucanlivewith.com/

[Guest guest]

I am also predicting kidney problems (and bone problems) for our

Adkins followers.

Healthygirl

> Colleagues, the following is FYI; I have no further knowledge of

the topic.

> ------------------------

> On the edge: Are we at risk of an ESRD pandemic?

> Worldwide increase in diabetes forecasts renal disease explosion

> http://www.eurekalert.org/pub_releases/2004-05/rc-ote051704.php

>

> An analysis of demographic data collected on European and American

> patients participating in studies for a new non-calcium phosphate

binder

> show striking differences between the causes of renal failure: 14%

of

> European renal failure patients had diabetes as their primary

diagnosis,

> whereas 34% of US patients had this diagnosis.2 If, as expected by

many

> experts, the incidence of diabetes in Europe (estimated by the WHO

to

> rise from 33 million in 2000 to over 48 million by 20303) grows to

match

> that of the US, demand for renal replacement therapy in end stage

renal

> disease (ESRD) could escalate sharply.

>

> " Patient demographic data from studies are extremely useful in

helping

> us understand the pattern of disease and the underlying causes of

renal

> failure " , commented lead investigator of the US study, Dr

F.

> Finn, Professor of Medicine, University of North Carolina School of

> Medicine. " The question we have to ask ourselves is whether Europe

will

> follow the US, where increasing obesity is driving up the

likelihood

> that diabetes numbers will increase, thereby increasing the

incidence of

> diabetes-related renal failure. "

>

> The studies in which these renal failure patients were enrolled

were set

> up to assess the efficacy and safety of FOSRENOL® (lanthanum

carbonate),

> a new phosphate binding medication recently granted its first

regulatory

> approval (in Sweden). Hyperphosphataemia (excessive levels of

phosphate

> in the blood) develops in up to 80% of patients on dialysis4 and

can

> lead to bone pain, skeletal deformities and fractures if left

untreated.

> It is also associated, in conjunction with elevated calcium levels,

with

> the development of cardiovascular disease, which accounts for

nearly 50%

> of all deaths in dialysis patients.5,6

>

> Baseline screening data from the new studies also illustrated the

> shortcomings of currently available hyperphosphataemia treatments.

At

> entry to the studies, calcium-based phosphate binders were the most

> commonly used medication, both in the US (93%) and Europe (65%).2

> However, serum phosphorus levels in these patients at study entry

were

> markedly higher than the target levels (3.5 to 5.5 mg/dL)

recommended by

> the new K/DOQI (Kidney Disease Outcomes Quality Initiative)

guidelines7,

> with a mean level of 6.6 mg/dL in the European patients and 6.2

mg/dL in

> the US patients.2

>

> In previous studies, FOSRENOL has been shown to be an effective and

well

> tolerated phosphate binder, lowering serum phosphate to target

levels

> within eight weeks and maintaining this long-term, with some

patients

> treated for 36 months (three years) or more.8,9 FOSRENOL therefore

> represents a promising option for hyperphosphataemia management.

>

> " There is no doubt that, with diabetes on the increase, end stage

renal

> disease will increase as well. To help our patients stay well, for

as

> long as possible while on dialysis, there is a pressing need for

new and

> effective treatments like FOSRENOL to help us manage serious

> complications such as hyperphosphataemia " , concluded Dr Alastair

> Hutchison, Manchester Institute of Nephrology & Transplantation,

UK, who

> led the European study.

> --

> ne Holden, MS, RD < fivestar@n... >

> " Ask the Parkinson Dietitian " http://www.parkinson.org/

> " Eat well, stay well with Parkinson's disease "

> " Parkinson's disease: Guidelines for Medical Nutrition Therapy "

> http://www.nutritionucanlivewith.com/